A carregar...
A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy
A preclinical trial identified 4 of 20 (20%) gastric cancer (GC) patient-derived xenografts responded to cetuximab. Genome-wide profiling and additional investigations revealed that high EGFR mRNA expression and immunohistochemistry score (3+) are associated with tumor growth inhibition. Furthermore...
Na minha lista:
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Nature Publishing Group
2013
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3801116/ https://ncbi.nlm.nih.gov/pubmed/24141978 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep02992 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|